N@N

ENDP, VRUS, RDY, TEO, SAPE, DT. Top Gainers With Lowest Price Friction In Morning Trade Today

^{Published on 2009-06-17 08:43:00, Last Modified on 2010-12-22 14:14:37 - WOPRAI}
 

June 17, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for June 17, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This fair market making requirement is designed to prevent market makers from manipulating stock prices. Here is a list of the top companies with the largest gains this morning and lowest price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Endo Pharmaceuticals (NASDAQ: ENDP), Pharmasset (NASDAQ: VRUS), Dr. Reddys Laboratories (NYSE: RDY), Telecom Argentina (NYSE: TEO), Sapient (NASDAQ: SAPE) and Deutsche Telekom (NYSE: DT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction

ENDP $0.53 3.18% 106,358 50.29% 104,945 49.62% 1,413 27

VRUS $0.39 3.58% 3,100 51.64% 2,903 48.36% 197 5

RDY $0.37 2.55% 20,000 41.74% 17,010 35.50% 2,990 81

TEO $0.32 3.10% 10,100 52.47% 7,950 41.30% 2,150 67

SAPE $0.30 5.11% 89,654 63.88% 49,299 35.13% 40,355 1,345

DT $0.29 2.66% 126,546 41.55% 122,121 40.09% 4,425 153

Click here to view chart:

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows ENDP with a dollar gain today of +$0.53 and a Friction Factor of 27 shares. That means that it only takes 27 more shares of buying than selling to move ENDP higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), a pharmaceutical company, engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain primarily in the United States. Its products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana ER and Opana for the relief of moderate-to-severe pain in patients; Percocet and Percodan tablets; Frova for the treatment of migraine headaches in adults; and Voltaren Gel for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company�s products also include Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Sanctura XR to treat OAB symptoms; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer; Delatestryl for the treatment of male hypogonadism; Hydron Implant; and Valstar, a sterile solution of valrubicin for intravesical instillation. Its development stage products include Nebido for treatment of hypogonadisml; PRO 2000, a Phase III clinical stage product for the prevention of infection by HIV and other sexually-transmitted pathogens; octreotide implant, a Phase III clinical stage product for the treatment of acromegaly; and axomadol, a Phase II clinical stage product for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company�s generic products include Morphine Sulfate and Endocet, an oxycodone hydrochloride and acetaminophen product. It has strategic alliances with Novartis AG, Hind Healthcare, Penwest Pharmaceuticals Co., and Vernalis Development Limited. The company was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania.

Pharmasset, Inc. (NASDAQ: VRUS), a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections. Its primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company has three product candidates under development, which include Clevudine, an oral, once-daily pyrimidine nucleoside analog, which is under Phase III clinical trials for the treatment of chronic HBV infection; R7128, a pro-drug of PSI-6130 has completed Phase I clinical trial for the treatment of HCV, through a collaboration with F. Hoffmann-LaRoche, Ltd. and Hoffmann-La Roche, Inc.; and Racivir, an oral, once-daily cytidine nucleoside analog, which has completed a Phase II clinical trial for the treatment of HIV. In addition, Pharmasset engages in the development of DFC, an oral, once-daily deoxycytidine nucleoside analog, for the treatment of HIV; and PSI-7851 for the treatment of HCV. It collaboration and licensing agreements with Boehringer Ingelheim Chemicals, Inc.; University of Cincinnati; Bukwang Pharm. Co., Ltd.; University of Georgia Research Foundation, Inc. and Yale University; Incyte Corporation; Emory University; and RFS Pharma LLC. The company was founded in 1998 and is based in Princeton, New Jersey.

Dr. Reddys Laboratories Limited (NYSE: RDY), together with its subsidiaries, operates as a pharmaceutical company. The company focuses on formulations, active pharmaceutical ingredients and intermediates, generic drugs, critical care products, biotechnology products, custom pharmaceutical services, and drug discovery. It conducts research in the areas of cancer, diabetes, metabolic disorders, cardiovascular diseases, inflammation, and bacterial infection. In addition, the company involves in contract manufacturing of generic prescription and over-the-counter products for branded and generic companies in the United States. Further, Dr. Reddy�s offers central nervous system, pain management, gastrointestinal, respiratory, anti-infective, urology, women�s health, spasticity, and alimentary tract related generics finished dosages. It markets its products in India, Russia, the United States, United Kingdom, Germany, South Africa, Brazil, China, Kazakhstan, Uzbekistan, Ukraine, Belarus, Vietnam, Romania, Venezuela, and Myanmar. The company has a co-development and commercialization agreement with Denmark based Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec International for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease; and an agreement with 7TM Pharma for the drug discovery collaboration on selected drug targets. Dr. Reddy�s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Telecom Argentina S.A. (NYSE: TEO), together with its subsidiaries, provides telephone services to residential and corporate customers in Argentina. It operates in two segments, Voice, Data, and Internet Services; and Wireless Telecommunication Services. The Voice, Data, and Internet Services segment provides fixed telephone services; international telecommunications services, including voice and data services, and international point-to-point leased circuits; data transmission and Internet services, such as private networks, dedicated lines, broadcasting signal transport, and videoconferencing services, as well as dial-up and broadband Internet connectivity services; and call forwarding, call waiting, calling cards, voice mail, and itemized billing services. The Wireless Telecommunication Services segment offers wireless telephone services via cellular and PCS networks. This segment also engages in the sale of wireless handsets to customers, agents, and various third-party distributors. As of December 31, 2008, the company served approximately 4.3 million fixed lines, 1.1 million broadband and Internet connections, and 14.4 million cellular subscribers. Telecom Argentina was formerly known as Telecom Argentina STET-France Telecom S.A. and changed its name to Telecom Argentina S.A. in February 2004. The company was founded in 1990 and is based in Buenos Aires, Argentina. Telecom Argentina S.A. is a subsidiary of Nortel Inversora S.A.

Sapient Corporation (NASDAQ: SAPE) provides business, marketing, and technology consulting services worldwide. It offers various interactive marketing and creative services, including visual concept, design, and implementation through multiple interactive media; brand building and direct response programs; audience segmentation and profiling strategies; customer loyalty strategies; customer relationship strategy and implementation; customer lead generation and management; and advertising campaigns. The company also provides Web and interactive development services that include user interface and site design and development, custom application development, user research and testing, content management, and technology development and implementation, as well as quality assurance testing; and media planning and buying services, which enable clients to design and implement media and customer channel planning and buying strategies, as well as purchase and arrange for placement of clients� advertisements. In addition, Sapient Corporation offers strategic planning and marketing analytics; and marketing technologies, such as advertising campaign tracking and measurement software, e-commerce platform, selection and implementation of advertising campaign management systems, and application integration. Further, the company provides consulting services to clients across four primary service areas comprising business and information technology strategy, business applications, business intelligence, and outsourcing; and trading and risk management services that enable capital markets and energy firms enhance the performance of their trading operations. It offers its services to media and entertainment, consumer/retail products, travel and hospitality, technology, communications, financial services, transportation, automotive, health care and life sciences, education, and energy and utility industries. The company was founded in 1990 and is headquartered in Boston, Massachusetts.

Deutsche Telekom AG (NYSE: DT) provides a range of telecommunications and information technology services worldwide. The company�s Mobile Communications segment offers digital mobile telephony voice services and data services, such as short message services, multimedia messaging services, and mobile Internet and other data services; and national and international roaming services through various roaming agreements with third-party operators, as well as sells mobile devices in conjunction with its services. Its Broadband/Fixed Network segment offers network communications services consisting of network access products and calling services; wholesale services, including voice services, Internet protocol (IP) services, and network and access services and solutions; IP/Internet products and services, such as broadband access, VoIP, IPTV, triple-play services, and digital distribution platforms for games, software, and music; data communications services and solutions, and terminal equipment for telecommunications, as well as publishing services, customer retention programs, and installation and maintenance services; and fixed-line network services, wholesale services, IP/Internet products and services, and multimedia services. The company�s Business Customers segment, through T-Systems division, provides information and communications technology services primarily to German and international companies, non-profit organizations, and governmental agencies. This segment offers telecommunication services, including network, hosting, and ASP services; and computing and desktop, systems integration, and other telecommunication services. Deutsche Telekom AG has a strategic partnership agreement with Yahoo!, Inc. for the development and provision of mobile search services based on Yahoo! oneSearch solution. The company was founded in 1995 and is based in Bonn, Germany.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,550,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net